GIP: what gastric inhibitory peptide does in the body

Why GIP has two names

A 2021 review traces the history. In 1971, Brown and Dryburgh reported the amino-acid sequence of a new gut peptide. They found it by its ability to lower acid release from dog stomach pouches. They named it gastric inhibitory polypeptide, shortened to GIP.

In 1973, Dupre and Brown reported that GIP raises insulin release. The review says the stomach-acid effect later proved unimportant in normal body function. The hormone was renamed glucose-dependent insulinotropic polypeptide. The new name kept the same letters, GIP.

Insulinotropic means it raises insulin release. Glucose-dependent means the effect needs raised blood sugar. Some papers shorten the old name to gastric inhibitory peptide. The reviewed UniProt record still lists the old name first and the newer name as an alternative.

How many amino acids GIP has

The reviewed human UniProt entry P09681 describes a starting chain of 153 amino acids. Cells cut this longer precursor to release GIP. The record places mature GIP at positions 52 through 93. That is exactly 42 amino acids.

The National Library of Medicine's MeSH record describes GIP as about 43 amino acids long. That record gives an approximate figure and names no exact chain. UniProt gives the exact count for the human hormone, so this post uses 42.

UniProt also places GIP in the glucagon family of peptides. Glucagon is a hormone that raises blood sugar. The family name describes related amino-acid sequences.

How GIP helps release insulin after a meal

GIP comes from K cells, a kind of hormone-making cell. A 2021 review places them in the duodenum and upper jejunum. These are the first parts of the small intestine after the stomach.

GIP and GLP-1 are the two known incretin hormones. GLP-1 stands for glucagon-like peptide-1, another gut hormone. An incretin is a gut hormone that boosts insulin release after eating. A 2018 review says swallowed glucose triggers two to three times more insulin than glucose given into a vein. The review credits this gap to the incretin hormones.

The 2018 review also lists GIP effects on fat cells and bone. Its abstract gives no study details for those effects. How strong is the evidence? The insulin role is supported by controlled studies in people, described below. The fat and bone effects are less certain from these records.

What a 2019 study found in healthy men

A 2019 randomized trial studied 18 healthy men. A receptor is a part of a cell that receives a signal. On separate days, the men received research blockers for the GIP receptor, the GLP-1 receptor, both, or neither.

Each day included a four-hour glucose drink test and a meal. Researchers measured insulin release as C-peptide compared with blood sugar. C-peptide is released with insulin. Compared with no blocker, it fell 30% with the GIP blocker and 37% with both blockers.

The GLP-1 blocker alone changed it by 8.6% on average, with wide variation between men. Blood sugar rose more when GIP was blocked than when GLP-1 was blocked. The authors concluded that natural GIP affected these measures more than natural GLP-1 did.

Some authors list affiliations with Antag Therapeutics and Zealand Pharma. How strong is the evidence? A small, controlled study supports that finding for healthy men under test conditions. It cannot describe women, people with diabetes or long-term effects.

What changes in type 2 diabetes

A 1993 study compared nine people with mild type 2 diabetes and nine matched people without it. Researchers infused synthetic human GIP or GLP-1 while holding blood sugar at a raised level.

With GIP, the largest insulin response in the diabetes group was 54% lower than in the comparison group. That gap was statistically significant. With GLP-1, the diabetes group reached 71% of the comparison group's C-peptide rise. That difference was not statistically significant.

GLP-1 also lowered glucagon, but GIP did not. A 2018 review says GIP's effect on the pancreas is substantially reduced in type 2 diabetes. How strong is the evidence? The 1993 study was small. That result applies to nine people with mild type 2 diabetes during short infusions under test conditions.

How an enzyme shortens natural GIP

An enzyme called dipeptidyl peptidase IV, or DPP-4, cuts the first two amino acids from GIP. A 1995 study in rats reported that this cut turns GIP(1-42) into GIP(3-42). The authors describe GIP(3-42) as biologically inactive.

Researchers infused rats with GIP tagged so they could track it. Over half was cut within two minutes. Rats without working DPP-4 did not make the shortened form. The authors warned that the lab tests used then might not tell the active and cut forms apart.

How strong is the evidence? These findings come from rats and laboratory tests only. The timing in people is outside what the study measured.

How tirzepatide relates to GIP

The Zepbound prescribing information, revised August 2026, calls tirzepatide a GIP receptor and GLP-1 receptor agonist. An agonist is a molecule that switches on a receptor. The label says tirzepatide activates both receptors.

The label says tirzepatide is based on the GIP sequence. It lists aminoisobutyric acid, an unusual amino acid, at positions 2 and 13. It also lists an amide at the end of the chain. Position 20 carries a fatty acid attached through a linker.

The label says the fatty acid helps the drug bind albumin, a blood protein, and last longer. It says nonclinical studies suggest GIP may add to food-intake control. Nonclinical means studies outside people, such as animal studies.

A 2021 review says GIP given alone has never reduced appetite in short human studies. It says the appetite effect of tirzepatide may come from GLP-1 action alone. Two review authors list work with Lilly, which makes tirzepatide. How strong is the evidence? The structure comes from the label, and the GIP appetite role remains unsettled.

Consider a hypothetical post that says tirzepatide is just GIP. The label record does not support that claim. Tirzepatide has changed amino acids, an added fatty acid and a second receptor target. Studies of natural GIP do not show tirzepatide's results or side effects.